Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 89« First...89101112...203040...Last »

Human antibodies made in cows could be developed to treat MERS

Human antibodies made in genetically engineered cows have proved safe in an early-stage clinical trial.

Read More »

Momenta, Mylan plan biosimilar clinical trial

Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.

Read More »

Sangamo, Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc. and Pfizer Inc. are partnering to develop a gene therapy to treat a disease that affects nerve cells in the brain and the spinal cord.

Read More »

Immune cells linked to very early spread of breast cancer

Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.

Read More »

Starting new COPD inhaler tied to heart attack risk

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.

Read More »

Drinking hot tea linked to lowered glaucoma risk

People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.

Read More »

Odonate Therapeutics Announces Initiation of Phase 3 Study for Metastatic Breast Cancer

Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.

Read More »

Supplements may not lower fracture risk

Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.

Read More »

Celgene’s Follicular Lymphoma Regimen Fails Phase III

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

Read More »

Three Hottest Areas of Drug Development to Keep an Eye on in 2018

The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.

Read More »

Shire’s Hunter Syndrome Treatment Fails Study Goals

Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.

Read More »

Allergan, Richter’s bipolar depression drug succeeds in key trial

Allergan and Gedeon Richter’s drug cariprazine to treat severe bipolar depression in adults met the main goal of a late-stage study.

Read More »

Keytruda Fails Phase III Stomach Cancer Study

Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Read More »

Bumper crop of new drugs fails to lift big pharma R&D returns

2017 has shaped up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Read More »

Genentech’s Hemlibra Data Wows at ASH

At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Read More »

Verastem Announces Pivotal Clinical Data

The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.

Read More »

Lilly’s Cyramza meets main goal for gastric cancer

Eli Lilly & Co.’s Cyramza met the main study goal but failed to improve survival rates in a late-stage trial for gastric cancer.

Read More »

Breast cancer drug superior to chemo in study

Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.

Read More »

Roche study: Cancer ‘Velcro’ halts T-cell attack

Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Read More »

Sage’s depression drug succeeds in study

Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

Read More »

Page 10 of 89« First...89101112...203040...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation